{"product_id":"65th-ash-annual-meeting-exposition","title":"65th ASH Annual Meeting \u0026 Exposition","description":"\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003ch2 class=\"subtitle\"\u003e65th ASH Annual Meeting \u0026amp; Exposition\u003c\/h2\u003e\n\u003cbr\u003eThe \u003cstrong\u003eAmerican Society of Hematology (ASH) Annual Meeting 2023  \u003c\/strong\u003e\u003cstrong\u003e65th ASH Annual Meeting \u0026amp; Exposition \u003c\/strong\u003e was a premier event in classical and malignant hematology. It provided an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. The \u003cstrong\u003ewebcasts\u003c\/strong\u003e from the 65th ASH Annual Meeting and Exposition are now available. These webcasts provide access to more than \u003cstrong\u003e400 hours\u003c\/strong\u003e of recorded content from the meeting, including oral abstract sessions.\u003cbr\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ch4\u003eInclude: 262 videos + 1193 pdfs, size: 96.7 GB\u003c\/h4\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003e\u003cstrong\u003e Topics:\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eEducation Program Acquired Hemophilia A Diagnosis and Management Andreas Tiede-24122.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Acquired Hemophilia A Diagnosis and Management Rebecca Kruse-Jarres-24122.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Acquired Hemophilia A Diagnosis and Management Sean Platton-24122.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Acquired Hemophilia A Diagnosis and Management.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Alphabet Soup – Challenging Consults on the Pediatric Units Ashish Kumar-24117.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Alphabet Soup – Challenging Consults on the Pediatric Units Clifford Takemoto-24117.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Alphabet Soup – Challenging Consults on the Pediatric Units Nicole Kucine-24117.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Alphabet Soup – Challenging Consults on the Pediatric Units.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Are We Personalizing MDS Therapy in 2023 David Sallman-24106.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Are We Personalizing MDS Therapy in 2023 Marie Sebert-24106.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Are We Personalizing MDS Therapy in 2023 Rena Xian-24106.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Are We Personalizing MDS Therapy in 2023.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program CAR T Cells in ALL Bridge or Definitive Therapy Alice Bertaina-24107.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program CAR T Cells in ALL Bridge or Definitive Therapy Nirali Shah-24107.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program CAR T Cells in ALL Bridge or Definitive Therapy Stephen Gottschalk-24107.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program CAR T Cells in ALL Bridge or Definitive Therapy.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Eduard Van Beers-24125.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Kevin Kuo-24125.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias Rachael Grace-24125.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Energizing the Red Cell Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kasiani Myers-24118.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Kristen Schratz-24118.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right Suneet Agarwal-24118.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes Too Early, Too Late, Just Right.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Idoroenyi Amanam-24100.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Kirk Schultz-24100.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure Muna Qayed-24100.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Graft Versus Host Disease Is an Ounce of Prevention Worth a Pound of Cure.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Have We Optimized Therapy Yet for Patients with AML Justin Watts-24104.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Have We Optimized Therapy Yet for Patients with AML Tara Lin-24104.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Have We Optimized Therapy Yet for Patients with AML.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologic Toxicity of Immunotherapies Frederick Locke-24113.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologic Toxicity of Immunotherapies Martin Hutchings-24113.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologic Toxicity of Immunotherapies Michael Kroll-24113.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologic Toxicity of Immunotherapies.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists and the Care of Pregnant Women Adam Lewkowitz-24121.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists and the Care of Pregnant Women Andra James-24121.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists and the Care of Pregnant Women Fionnuala Ni Ainle-24121.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists and the Care of Pregnant Women.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists as Lifesavers Inpatient Hematology Emergencies Adi Zoref-Lorenz-24124.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists as Lifesavers Inpatient Hematology Emergencies Martin Tallman-24124.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists as Lifesavers Inpatient Hematology Emergencies Steven Fein-24124.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hematologists as Lifesavers Inpatient Hematology Emergencies.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Hemostasis in Patients With Severe Liver Disease Lara Roberts-24123.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hemostasis in Patients With Severe Liver Disease Ton Lisman-24123.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hemostasis in Patients With Severe Liver Disease Walter Ageno-24123.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hemostasis in Patients With Severe Liver Disease.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Hot Topics in Blood Donation Donor Risks and Social Justice Darja Karpova-24119.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hot Topics in Blood Donation Donor Risks and Social Justice Mindy Goldman-24119.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hot Topics in Blood Donation Donor Risks and Social Justice Richard Kaufman-24119.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Hot Topics in Blood Donation Donor Risks and Social Justice.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Can We Manage High-Risk Hematologic Malignancies in the Community Dipti Patel-Donnelly-24110.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Can We Manage High-Risk Hematologic Malignancies in the Community Jesus Berdeja-24110.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Can We Manage High-Risk Hematologic Malignancies in the Community Ruemu Birhiray-24110.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Can We Manage High-Risk Hematologic Malignancies in the Community.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Nizar Bahlis-24102.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Sham Mailankody-24102.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies Surbhi Sidana-24102.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma CAR T-Cells and Bispecific Antibodies.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Anna Maria Sureda Balari-24097.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Loretta Nastoupil-24097.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023 Manali Kamdar-24097.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Calibrate Cellular Therapy for Lymphoma in 2023.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Enhance Results in Rare Hematologic Malignancies Anita DSouza-24112.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Enhance Results in Rare Hematologic Malignancies Deepti Radia-24112.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Enhance Results in Rare Hematologic Malignancies Oussama Abla-24112.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Enhance Results in Rare Hematologic Malignancies.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Chaitra Ujjani-24111.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Joanna Rhodes-24111.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023 Toby Eyre-24111.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Adam Cohen-24103.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Francesca Gay-24103.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023 Monique Hartley-Brown-24103.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Tackle Remaining Clinical Challenges in CML Massimo Breccia-24109.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Tackle Remaining Clinical Challenges in CML Naranie Shanmuganathan-24109.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Tackle Remaining Clinical Challenges in CML Simona Soverini-24109.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How Do We Tackle Remaining Clinical Challenges in CML.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Andrew Evens-24098.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Natalie Grover-24098.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023 Sairah Ahmed-24098.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Adetola Kassim-24127.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle John Tisdale-24127.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle Kenneth Ataga-24127.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Improving Outcomes for Individuals With Sickle Cell Disease Are We Moving the Needle.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Emma Groarke-24126.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Marena Niewisch-24126.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult Timothy Olson-24126.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Inherited Bone Marrow Failure Syndromes – From Pediatrics to Adult.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Emily Curran-24108.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL John Molina-24108.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL Tamara Miller-24108.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Not Kids Anymore and Not Adults Yet How Do We Treat Adolescent and Young Adult (AYA) Patients With ALL.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Ongoing Challenges in the Management of VTE Cecilia Becattini-24115.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Ongoing Challenges in the Management of VTE Keith McCrae-24115.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Ongoing Challenges in the Management of VTE Kenneth Bauer-24115.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Ongoing Challenges in the Management of VTE.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program The Iron Revolution Jacquelyn Powers-24116.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program The Iron Revolution Michael Auerbach-24116.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program The Iron Revolution Thomas Deloughery-24116.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program The Iron Revolution.ts\u003c\/li\u003e\n\u003cli\u003eEducation Program Transfusion Support in Sickle Cell Disease Anoosha Habibi-24120.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Transfusion Support in Sickle Cell Disease France Pirenne-24120.pdf\u003c\/li\u003e\n\u003cli\u003eEducation Program Transfusion Support in Sickle Cell Disease Shannon Kelly-24120.pdf\u003cbr\u003eEducation Program Transfusion Support in Sickle Cell Disease.ts\u003cbr\u003eEducation Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Douglas Tremblay-24099.pdf\u003cbr\u003eEducation Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Harinder Gill-24099.pdf\u003cbr\u003eEducation Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management Jeanne Palmer-24099.pdf\u003cbr\u003eEducation Program What Are the Advances in Myeloproliferative Neoplasms Affecting Management.ts\u003cbr\u003eEducation Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Alison Walker-24105.pdf\u003cbr\u003eEducation Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Jacqueline Cloos-24105.pdf\u003cbr\u003eEducation Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML Marion Subklewe-24105.pdf\u003cbr\u003eEducation Program What are Treatment Options for Patients with Relapsed, Refractory or Persistent AML.ts\u003cbr\u003eEducation Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Asmita Mishra-24101.pdf\u003cbr\u003eEducation Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Reena Jayani-24101.pdf\u003cbr\u003eEducation Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together Roni Shouval-24101.pdf\u003cbr\u003eEducation Program What Makes a Good Transplant Recipient Putting the Puzzle Pieces Together.ts\u003cbr\u003eEducation Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Jennifer McIntosh-24114.pdf\u003cbr\u003eEducation Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies Shruti Chaturvedi-24114.pdf\u003cbr\u003eEducation Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies TBD Retter-24114.pdf\u003cbr\u003eEducation Program Why Am I Getting Paged at 2AM Microangiopathic Emergencies.ts\u003cbr\u003eGeneral Sessions ASH-EHA Joint Symposium Alexander Medvinsky-24135.pdf\u003cbr\u003eGeneral Sessions ASH-EHA Joint Symposium Linheng Li-24135.pdf\u003cbr\u003eGeneral Sessions ASH-EHA Joint Symposium.ts\u003cbr\u003eGeneral Sessions E. Donnall Thomas Lecture and Prize Katayoun Rezvani-24174.pdf\u003cbr\u003eGeneral Sessions E. Donnall Thomas Lecture and Prize.ts\u003cbr\u003eGeneral Sessions Ernest Beutler Lecture and Prize Johnny Mahlangu-24175.pdf\u003cbr\u003eGeneral Sessions Ernest Beutler Lecture and Prize Takehisa Kitazawa-24175.pdf\u003cbr\u003eGeneral Sessions Ernest Beutler Lecture and Prize.ts\u003cbr\u003eGeneral Sessions Ham-Wasserman Lecture Andreas Greinacher-24133.pdf\u003cbr\u003eGeneral Sessions Ham-Wasserman Lecture.ts\u003cbr\u003eGeneral Sessions Late Breaking Abstracts Adetola Kassim-25508.pdf\u003cbr\u003eGeneral Sessions Late Breaking Abstracts Hamish Scott-25508.pdf\u003cbr\u003eGeneral Sessions Late Breaking Abstracts Ibrahim Aldoss-25508.pdf\u003cbr\u003eGeneral Sessions Late Breaking Abstracts Keith McCrae-25508.pdf\u003cbr\u003eGeneral Sessions Late Breaking Abstracts Michael Wang-25508.pdf\u003cbr\u003eGeneral Sessions Late Breaking Abstracts Pieter Sonneveld-25508.pdf\u003cbr\u003eGeneral Sessions Late Breaking Abstracts.ts\u003cbr\u003eGeneral Sessions Plenary Scientific Session Banu Aygun-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Betty Pace-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Brian Krum-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Daniel Wolff-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Francesca Gay-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Isaac Odame-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Pamela Ting-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Peter Voorhees-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Salima Benbarche-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Stefanie Sarantopoulos-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Stephanie Halene-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session Trista North-25390.pdf\u003cbr\u003eGeneral Sessions Plenary Scientific Session.ts\u003cbr\u003eGeneral Sessions Presidential Symposium Claudia Kemper-24134.pdf\u003cbr\u003eGeneral Sessions Presidential Symposium Eleni Gavriilaki-24134.pdf\u003cbr\u003eGeneral Sessions Presidential Symposium Lubka Roumenina-24134.pdf\u003cbr\u003eGeneral Sessions Presidential Symposium.ts\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Hsiang-Ying Lee-24504.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Lei Yu-24504.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Marlies Rossmann-24504.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Meng Zhang-24504.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Vincent Schulz-24504.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation Xiurui Lv-24504.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Emerging Gene Regulatory Mechanisms in Erythroid Differentiation.ts\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rajesh Gunage-24503.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Rebecca Griffiths-24503.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Xu Han-24503.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yajing Chu-24503.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease Yuefeng Tang-24503.pdf\u003cbr\u003eOral Abstracts 101. Red Cells and Erythropoiesis, Excluding Iron Red Cells Erythropoiesis in Stress and Disease.ts\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Caroline Philpott-24505.pdf\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Gayle Ross-24505.pdf\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Ilona Kleine Budde-24505.pdf\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Rachel Josselsohn-24505.pdf\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Tomas Ganz-24505.pdf\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis Veena Sangkhae-24505.pdf\u003cbr\u003eOral Abstracts 102. Iron Homeostasis and Biology Exploring Molecular Mechanisms and Therapeutic Options in Iron Homeostasis.ts\u003cbr\u003eOral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Alfonso Fernandez-24506.pdf\u003cbr\u003eOral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Eugene Khandros-24506.pdf\u003cbr\u003eOral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Ginette Balbin-Cuesta-24506.pdf\u003cbr\u003eOral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Pinyaphat Khamphikham-24506.pdf\u003cbr\u003eOral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia Yu Wang-24506.pdf\u003cbr\u003eOral Abstracts 112. Thalassemia and Globin Gene Regulation Finding New Pathways to Treat Thalassemia.ts\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Auria Godard-24507.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Boya Liu-24507.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Britney Hernandez-24507.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Luisanna Sanchez Ventura-24507.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Mira Pochron-24507.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease Scott Peslak-24507.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Emerging Therapies for Sickle Cell Disease.ts\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Anton Ilich-24508.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Christopher Chambliss-24508.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Jason Sutin-24508.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Malgorzata Kasztan-24508.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Marissa Traets-24508.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans Suruchi Salgar-24508.pdf\u003cbr\u003eOral Abstracts 113. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Basic and Translational Pathophysiology of Sickle Hemoglobinopathies From Mice to Humans.ts\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Alan Anderson-24511.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Angela Rankine-Mullings-24511.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Pablo Pelinski-24511.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Robyn Cohen-24511.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation Sophie Lanzkron-24511.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Advances in Clinical Care and Implementation.ts\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Miguel Abboud-24512.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Modupe Idowu-24512.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Nirmish Shah-24512.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Santosh Saraf-24512.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Shubaya Naggayi-24512.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease Swee Lay Thein-24512.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Building on Momentum in Disease-Modifying Therapeutics for Sickle Cell Disease.ts\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Anna Sowa-24509.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Dunia Hatabah-24509.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Julie Kanter-24509.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mariane De Montalembert-24509.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Mehndi Dandwani-24509.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors Modupe Idowu-24509.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Hot Topics in Clinical Care and Genomic Factors.ts\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Clare Zarka-24510.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Jackie Queen-24510.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Justin Yoo-24510.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Kristine Karkoska-24510.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Martha Kenney-24510.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future Ryan Sun-24510.pdf\u003cbr\u003eOral Abstracts 114. Sickle Cell Disease, Sickle Cell Trait and Other Hemoglobinopathies, Excluding Thalassemias Clinical and Epidemiological Sickle Cell Treatment Present and Future.ts\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Adi Zoref-Lorenz-24514.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Chen Li-24514.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Coralie Bloch-24514.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Misato Komori-24514.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Ningning Zhang-24514.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes Peter Dimitrion-24514.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages Granulocytes, Monocytes and Disorders of Histocytes.ts\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Christina Simoglou Karali-24513.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Danielle Arnold-24513.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Malte Ritter-24513.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias Vahagn Makaryan-24513.pdf\u003cbr\u003eOral Abstracts 201. Granulocytes, Monocytes, and Macrophages New Insights into Inherited and Acquired Neutropenias.ts\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Benjamin Babcock-24515.pdf\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Carlos Bravo-Perez-24515.pdf\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Dandan Wang-24515.pdf\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Francesco Saettini-24515.pdf\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Mei Yu-24515.pdf\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity Melissa Mavers-24515.pdf\u003cbr\u003eOral Abstracts 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders Decoding the Complex Landscape of Human Immunity Insights From Genetic Mutations to Cellular Heterogeneity.ts\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Anish Sharda-24518.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Huichun Zhan-24518.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Junmei Chen-24518.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Kelsey Sack-24518.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Luke Dunaway-24518.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis Nilesh Pandey-24518.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Insights Into the Role of Endothelium in Cardiovascular Disease and Thrombosis.ts\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Adam Kanack-24517.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Caitlin Schneider-24517.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Cristobal Rivera-24517.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Meghna Naik-24517.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Moua Yang-24517.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis Yvonne Kong-24517.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational Targeting platelet reactivity in thrombosis.ts\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Anthony Washington-24516.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Harvey Roweth-24516.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Heng Mei-24516.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Jianlin Qiao-24516.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Lauren Murphy-24516.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias Yuxiu Chen-24516.pdf\u003cbr\u003eOral Abstracts 301. Vasculature, Endothelium, Thrombosis and Platelets Basic and Translational The Multimodal Platelet; Discovery of Novel Platelet Functions and Applications From Cancers to Thrombocytopenias.ts\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Ahmad Tarawah-24521.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anna Frandsen-24521.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Anne Juhl-24521.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes David Kuter-24521.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Elizabeth King-24521.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes Hanny Al-Samkari-24521.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Clinical Practice, Natural History, and Patient Reported Outcomes.ts\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Catherine Broome-24519.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Michael Tarantino-24519.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Min Xu-24519.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Nichola Cooper-24519.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia Yun Wang-24519.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Innovative Treatments for Immune Thrombocytopenia.ts\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Bertrand Godeau-24520.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Cy Wilkins-24520.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Etienne Crickx-24520.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Taylor Kim-24520.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yoann Zadro-24520.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations Yuxiu Chen-24520.pdf\u003cbr\u003eOral Abstracts 311. Disorders of Platelet Number or Function Clinical and Epidemiological Thrombocytopenia in Special Populations.ts\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Aleksandr Shamanaev-24522.pdf\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Lucas Van Gorder-24522.pdf\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Meng-Ni Fan-24522.pdf\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Shekhar Kumar-24522.pdf\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Thomas Girard-24522.pdf\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies Wenjing Cao-24522.pdf\u003cbr\u003eOral Abstracts 321. Coagulation and Fibrinolysis Basic and Translational Coagulation Protein Molecular Insights and Molecular Therapies.ts\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Davide Matino-24525.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Evelien Krumb-24525.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Guy Young-24525.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Marilyn Manco-Johnson-24525.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care Yeu-Chin Chen-24525.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Beyond the Numbers Non-Factor Factors in Bleeding Disorder Care.ts\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Allison Wheeler-24523.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Ferdows Atiq-24523.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Lynn Malec-24523.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan Steven Pipe-24523.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Bleeding Disorder Management Throughout the Lifespan.ts\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Aditi Sharma-24524.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Anthony Chan-24524.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Ellen Zhang-24524.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Eva Leinoe-24524.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Rachel Kronenfeld-24524.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders Valentina Restrepo-24524.pdf\u003cbr\u003eOral Abstracts 322. Disorders of Coagulation or Fibrinolysis Clinical and Epidemiological Out of the Box Acquired, Vascular and Other Neglected Bleeding Disorders.ts\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Kenki Saito-24526.pdf\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marie Scully-24526.pdf\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Marissa Schraner-24526.pdf\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Maryam Subhan-24526.pdf\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Omid Peyvandi-24526.pdf\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations Senthil Sukumar-24526.pdf\u003cbr\u003eOral Abstracts 331. Thrombotic Microangiopathies Thrombocytopenias and COVID-19-Related Thrombotic Vascular Disorders Clinical and Epidemiological New Frontiers in TTP Diagnostic and Therapeutic Innovations.ts\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Bec.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Jus.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Kri.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care She.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care Sim.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Cancer Associated Thrombosis (CAT) Understanding Risk as a Potential Means to Improve Patient Care.ts\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Amelia Haj-24528.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Gary Woods-24528.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Julie Jaffray-24528.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Justine Ryu-24528.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Sacha Belinda Mapombo Choupa-24528.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism Vilmarie Rodriguez-24528.pdf\u003cbr\u003eOral Abstracts 332. Thrombosis and Anticoagulation Clinical and Epidemiological Genetics, Pregnancy, and Pediatrics Advances in Venous Thromboembolism.ts\u003cbr\u003eOral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Lise McQuilten-24529.pdf\u003cbr\u003eOral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Matthew Tanner-24529.pdf\u003cbr\u003eOral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Nanyan Zhang-24529.pdf\u003cbr\u003eOral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Patricia Davenport-24529.pdf\u003cbr\u003eOral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine Slim Azouzi-24529.pdf\u003cbr\u003eOral Abstracts 401. Blood Transfusion Advances in Transfusion Medicine.ts\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alejandro Roisman-24781.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Alison Livada-24781.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Helen Wang-24781.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Stephanie Hurwitz-24781.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Takao Yogo-24781.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness Tanner Martinez-24781.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Cell Fate Decisions and Fitness.ts\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Aditya Barve-24530.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Karolina Vanickova-24530.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Maegan Capitano-24530.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Md Akram Hossain-24530.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Virginia Camacho-24530.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress Yiran Meng-24530.pdf\u003cbr\u003eOral Abstracts 501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis Basic and Translational Inflammation, Metabolism, and Stress.ts\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Lynn Quek-24532.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Nikolaos Sousos-24532.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Saravanan Ganesan-24532.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries Sean Wen-24532.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation From Omics to Discoveries.ts\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Adriana Chiaramida-24531.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations J. Beeler-24531.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Johannes Damm-24531.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Nicole Prutsch-24531.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations Yifan Zhou-24531.pdf\u003cbr\u003eOral Abstracts 503. Clonal Hematopoiesis, Aging and Inflammation Translational Innovations.ts\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Charles Ayemoba-24533.pdf\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Dinisha Kamble-24533.pdf\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Eman Khatib-Massalha-24533.pdf\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Irene Ganan-Gomez-24533.pdf\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Rheanna Congdon-24533.pdf\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease Shoichiro Takeishi-24533.pdf\u003cbr\u003eOral Abstracts 506. Bone Marrow Microenvironment Bone Marrow Microenvironment in Health and Disease.ts\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Bhavisha Patel-24535.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carlos Bravo-Perez-24535.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Carmelo Gurnari-24535.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Masanori Yoshida-24535.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Pedro Prata-24535.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment Yoshitaka Zaimoku-24535.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Immune AA and VEXAS – Biology, Diagnosis and Treatment.ts\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Antonio Risitano-24534.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Austin Kulasekararaj-24534.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Carlos de Castro-24534.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Fengkui Zhang-24534.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials Jens Panse-24534.pdf\u003cbr\u003eOral Abstracts 508. Bone Marrow Failure Acquired Unraveling the Future of PNH Therapy From Clinical Trials.ts\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc .Kendra Jackson-24536.pdf\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Johan Flygare-24536.pdf\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Mona M.Hosseini-24536.pdf\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Seth Rotz-24536.pdf\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Valeria Visconte-24536.pdf\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc. Y. Lucy Liu-24536.pdf\u003cbr\u003eOral Abstracts 509. Bone Marrow Failure and Cancer Predisposition Syndromes Congenital and Misc..ts\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Bac Viet Le-24538.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Chun-Wei Chen-24538.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Qingyu Luo-24538.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Thomas Koehnke-24538.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xiangguo Shi-24538.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells Xin He-24538.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Chemical and Genetic Approaches for Targeting Leukemic Stem Cells.ts\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Ayana Kon-24537.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Cailin Collins-24537.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jane Xu-24537.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jie Bai-24537.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy Jonny Mendoza-Castrejon-24537.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Mechanisms and Models of Myeloid Malignancy.ts\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Dorien Pastoors-24539.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Luca Nunzio Cifarelli-24539.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Madeline Niederkorn-24539.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Prajwal Boddu-24539.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics Yu-Hsuan Chang-24539.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic RNA Splicing, Transcription, and Chromatin Dynamics.ts\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Amanda Tajik-24540.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Cl‚ment Larrue-24540.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Daiki Karigane-24540.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Junya Sango-24540.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms Sarah Skuli-24540.pdf\u003cbr\u003eOral Abstracts 602. Myeloid Oncogenesis Basic Therapeutic Strategies and Cellular Mechanisms.ts\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Darko Barisic-24541.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Gabriel Brisou-24541.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Mirca Saurty-Seerunghen-24541.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Ruifeng Sun-24541.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis Sergio Roa-24541.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Epigenetic, Immune-Related, and Signaling Mechanisms of Lymphomagenesis.ts\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression I-Jun Lau-24542.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Marta Fernandes-24542.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Nataly Cruz-Rodriguez-24542.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Qi Jin-24542.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression Vera Poort-24542.pdf\u003cbr\u003eOral Abstracts 603. Lymphoid Oncogenesis Basic Mechanisms of Acute Lymphoblastic Leukemia Development and Progression.ts\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Claudia Cabrera-24545.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Eric Vick-24545.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Karanpreet Bhatia-24545.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Lei Zhang-24545.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Sana Chaudhry-24545.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies Tim Kong-24545.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Personalized and Combinatorial Approaches to Target Vulnerabilities in Myeloid Malignancies.ts\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Kedwin Ventura-24543.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Li Du-24543.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Priyanka Sharma-24543.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Satoshi Kaito-24543.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies Zhixiang Chen-24543.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Strategies to Overcome Therapy Resistance in Myeloid Malignancies.ts\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Anagha Sheth-24544.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Juan Jose Rodriguez Sevilla-24544.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Vincent Rondeau-24544.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Xinyue Zhou-24544.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yi Zhang-24544.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies Yuki Nishida-24544.pdf\u003cbr\u003eOral Abstracts 604. Molecular Pharmacology and Drug Resistance Myeloid Neoplasms Therapeutic Implications of Leukemia Stem Cells and Differentiation in Myeloid Malignancies.ts\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Damian Green-24546.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Keito Suto-24546.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Leandro Cerchietti-24546.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Nathan Beals-24546.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma Selina Chen-Kiang-24546.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Novel Therapeutic Approaches in Lymphoma and Multiple Myeloma.ts\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Britten Gordon-24547.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Giulia Veltri-24547.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Gregory Crimmins-24547.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Jasmeet Sidhu-24547.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Qin Li-24547.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias Thomas Lew-24547.pdf\u003cbr\u003eOral Abstracts 605. Molecular Pharmacology and Drug Resistance Lymphoid Neoplasms Targeted Therapy in Lymphoid Leukemias.ts\u003cbr\u003eOral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Aman Wadhwa-24548.pdf\u003cbr\u003eOral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Motohiro Kato-24548.pdf\u003cbr\u003eOral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Noam Kopmar-24548.pdf\u003cbr\u003eOral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Sarah Elitzur-24548.pdf\u003cbr\u003eOral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL Stuart Winter-24548.pdf\u003cbr\u003eOral Abstracts 612. Acute Lymphoblastic Leukemias Clinical and Epidemiological Progress Through Collaboration Impactful Cooperative Efforts to Optimize Care for ALL.ts\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Curtis Lachowiez-24549.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Enrico Attardi-24549.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Pinkal Desai-24549.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Rabea Mecklenbrauck-24549.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Vikram Dhillon-24549.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related Wajma Shahbaz-24549.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – De Novo and Myelodysplasia-Related.ts\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Erika Cattaneo-24550.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Georgina Gener-Ricos-24550.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Himachandana Atluri-24550.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Matthew Schwede-24550.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Riya Sinha-24550.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI Xin Wang-24550.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological AML – Molecular Targets, Ethnicity, and AI.ts\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Alex Bataller-24551.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Constance Baer-24551.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Marius Bill-24551.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Niek Van Der Maas-24551.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Richard Aplenc-24551.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication Yazan Abu-Shihab-24551.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Innovations in Prognostication.ts\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Cameron Hunter-24552.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches David Grinblatt-24552.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches James Foran-24552.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Talha Badar-24552.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches Zofia Gross-24552.pdf\u003cbr\u003eOral Abstracts 613. Acute Myeloid Leukemias Clinical and Epidemiological Real World Outcomes and Treatment Approaches.ts\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jayastu Jain-24554.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Jonathan Webster-24554.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Marlise Luskin-24554.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicola Goekbuget-24554.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Nicolas Boissel-24554.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL Wanda Salzer-24554.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Therapies for ALL.ts\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Karen Rabin-24553.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Martin Schrappe-24553.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Nicola Goekbuget-24553.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Sabina Chiaretti-24553.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Tanja Gruber-24553.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL Xiaoyuan Gong-24553.pdf\u003cbr\u003eOral Abstracts 614. Acute Lymphoblastic Leukemias Therapies, Excluding Transplantation and Cellular Immunotherapies Optimal Frontline Treatment for ALL.ts\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML B. Smith-24555.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Harry Erba-24555.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Himachandana Atluri-24555.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Hunault-Berger Mathilde-24555.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Jing Lu-24555.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML Xiaohui Suo-24555.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Improving Intensive Chemotherapy Regimens for Treatment of AML.ts\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Andrew Moore-24557.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Fabio Guolo-24557.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Franco Locatelli-24557.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Kristoffer Hellstrand-24557.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Li Gao-24557.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL Luca Guarnera-24557.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Long-Term Outcomes for Children and Adults Diagnosed With AML APL.ts\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexander Perl-24556.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Alexandre Kadia-24556.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Gertjan Kaspers-24556.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Nigel Russell-24556.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Xiaoping Liang-24556.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML Yunxiang Zhang-24556.pdf\u003cbr\u003eOral Abstracts 615. Acute Myeloid Leukemias Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies Refining Chemotherapy Regimens Plus Minus MRD Evaluation to Optimize Outcomes in AML.ts\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Guillaume Richard-Carpentier-24558.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Harinder Gill-24558.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Leo Ruhnke-24558.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Musa Yilmaz-24558.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Naval Daver-24558.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents Sylvain Garciaz-24558.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Novel Uses of Approved Therapeutic Agents.ts\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Elias Jabbour-24559.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Ghayas Issa-24559.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Li Yang-24559.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Robert Zeiser-24559.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Sara Zarnegar-Lumley-24559.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML Yuchen Liu-24559.pdf\u003cbr\u003eOral Abstracts 616. Acute Myeloid Leukemias Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies Upcoming Therapies in Newly Diagnosed and Relapsed Refractory AML.ts\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Eduardo Magalhaes-24564.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Fanny Gonzales-24564.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Nastassja Scheidegger-24564.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics Ramprasad Ramakrishnan-24564.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics V‚ronique Lisi-24564.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Biomarkers and Therapeutics.ts\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Andrew Stiff-24561.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Diego Pereira-Martins-24561.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Francisco Marchi-24561.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Juan Barajas-24561.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Martina Pigazzi-24561.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features Yotaro Ochi-24561.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Deciphering Risk by Genetic and Epigenetic Features.ts\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Bettina Nadorp-24562.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Danielle Kirkey-24562.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Isabel Weinhaeuser-24562.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control Sergio Rutella-24562.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Immunologic and Metabolic Biomarkers of Disease Control.ts\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Chong Chyn Chua-24563.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Corentin Orvain-24563.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Gege Gui-24563.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jacqueline Cook-24563.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Jad Othman-24563.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response Maddalena Benetton-24563.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Minimal Residual Disease and Therapy Response.ts\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Adrian Mosquera Orgueira-24560.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Curtis Lachowiez-24560.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Mark Levis-24560.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Pierre Peterlin-24560.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Romane Joudinaud-24560.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant Shai Shimony-24560.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Response Predictors to Targeted Therapies and Transplant.ts\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Adriane Halik-24565.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Gregor Hoermann-24565.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Hussein Abbas-24565.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response Sander Lambo-24565.pdf\u003cbr\u003eOral Abstracts 617. Acute Myeloid Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Risk Refinement and Therapy Response.ts\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Hanna Thorsson-24566.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Ilaria Iacobucci-24566.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Jingliao Zhang-24566.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Lorenz Bastian-24566.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis Shunsuke Kimura-24566.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Novel Disease Subclassifications and Clinical Prognosis.ts\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Anna Gurevich Shapiro-24567.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Francesco Corrado-24567.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Guranda Chitadze-24567.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Satoshi Yoshimura-24567.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Sean Tracy-24567.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment Willem Cox-24567.pdf\u003cbr\u003eOral Abstracts 618. Acute Lymphoblastic Leukemias Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis Targeted Therapies and The Immune Microenvironment.ts\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alan Cooper-24568.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Alicia Beyou-24568.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Andrew Feldman-24568.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics James Phelan-24568.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Natasha Lewis-24568.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics Sandrine Roulland-24568.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Insights into Lymphoma Unraveling the Molecular Complexity for Precision Diagnostics and Therapeutics.ts\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Alexis Claudel-24569.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Fabrice Jardin-24569.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Julia Paczkowska-24569.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Kyoko Yamaguchi-24569.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc Tomohiro Aoki-24569.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Microenvironment and Methylome in Lymphoma and Misc.ts\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Joseph Schroers-Martin-24570.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Pantaleo De Simone-24570.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Reid Merryman-24570.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Wen-Hsuan Wendy Lin-24570.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma Xiyue Xu-24570.pdf\u003cbr\u003eOral Abstracts 621. Lymphomas Translational – Molecular and Genetic Signaling Pathways and MRD in Lymphoma.ts\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Dylan Tatterton-24573.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jon Arnason-24573.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Jose A. Martinez-Climent-24573.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Ken Young-24573.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma Yusuke Isshiki-24573.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Elucidating Biomarkers and Mechanisms of Therapy in Lymphoma.ts\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Ilja Kalashnikov-24572.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Kanutte Huse-24572.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Matias Autio-24572.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma Vignesh Shanmugam-24572.pdf\u003cbr\u003eOral Abstracts 622. Lymphomas Translational – Non-Genetic Illuminating the Tumor Microenvironment and Immune Landscape in Lymphoma.ts\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Franck Morschhauser-24574.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Jonathan Friedberg-24574.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Lorenzo Falchi-24574.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy Stephen Schuster-24574.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Immunotherapy.ts\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emanuele Zucca-24577.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Emmanuel Bachy-24577.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Jillian Gunther-24577.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Loic Ysebaert-24577.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Morgane Cheminant-24577.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL Yucai Wang-24577.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective and Real-World Outcomes of Novel Therapies in Indolent Lymphomas and MCL.ts\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Anita Kumar-24576.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Carlo Visco-24576.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Craig Portell-24576.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Eliza Hawkes-24576.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents Michael Wang-24576.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Prospective Clinical Trials in Mantle Cell Lymphoma Incorporating Novel Agents.ts\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Clementine Sarkozy-24575.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Jonathon Cohen-24575.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Juan Alderuccio-24575.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Paolo Strati-24575.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Umberto Vitolo-24575.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy Vincent Ribrag-24575.pdf\u003cbr\u003eOral Abstracts 623. Mantle Cell, Follicular and Other Indolent B Cell Lymphomas Clinical and Epidemiological Targeted Therapy.ts\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Catherine Diefenbach-24580.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Elizabeth Phillips-24580.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Hun Lee-24580.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma Jeremy Abramson-24580.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in the Treatment of Hodgkin Lymphoma.ts\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Eric Jacobsen-24578.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Seok Jin Kim-24578.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Steven Horwitz-24578.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas Yuqin Song-24578.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Advances in Treating T Cell Lymphomas.ts\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Alison Moskowitz-24579.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Jonathan Brammer-24579.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Pierluigi Porcu-24579.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sanjal Desai-24579.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Sarah Rutherford-24579.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas Thais Fischer-24579.pdf\u003cbr\u003eOral Abstracts 624. Hodgkin Lymphomas and T NK Cell Lymphomas Clinical and Epidemiological Topics in T Cell, Szary and Hodgkin Lymphomas.ts\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Adam Olszewski-24582.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Clementine Sarkozy-24582.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jason Westin-24582.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Jillian Simard-24582.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas Lorenzo Falchi-24582.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Initial treatment strategies in aggressive B Cell lymphomas.ts\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Charalambos Andreadis-24583.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Christopher Melani-24583.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Gerhard Held-24583.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Martin Hutchings-24583.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma Sabarish Ayyappan-24583.pdf\u003cbr\u003eOral Abstracts 626. Aggressive Lymphomas Prospective Therapeutic Trials Novel Therapies For Relapsed Refractory Aggressive Lymphoma.ts\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Chan Cheah-24584.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Elizabeth Lihua Budde-24584.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Emil Kyvsgaard-24584.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Peter Riedell-24584.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas Trent Wang-24584.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Aiming for the Right Target Using CAR-T and Bispecifics in Aggressive Lymphomas.ts\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jelena Jelicic-24585.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jinhua Liang-24585.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Jordan Goldstein-24585.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Mark Roschewski-24585.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas Norbert Schmitz-24585.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Diagnostic and Prognostic Implications in the Care of Patients With Aggressive Lymphomas.ts\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Aung Tun-24588.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Gloria Iacoboni-24588.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Jean Koff-24588.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Loretta Nastoupil-24588.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Sanjal Desai-24588.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents Viktoriya Zelikson-24588.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Outcomes of Relapsed Refractory DLBCL Treated with Immunochemotherapy, CAR-T Cell and Novel Agents.ts\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Arushi Khurana-24589.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Brian Sworder-24589.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Fabian Frontzek-24589.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Pallawi Torka-24589.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL Steven Bair-24589.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Real World Data on Outcomes and Treatment-Related Toxicity in B Cell NHL.ts\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Andrew Zelenetz-24586.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Rena Buckstein-24586.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient Shinpei Harada-24586.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Treatment to Best Outcomes Find the Right Therapy for the Right Patient.ts\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Bhausaheb Bagal-24587.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL David Hodgson-24587.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Evelyn Orlando-24587.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Kathryn Lurain-24587.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Monica Balzarotti-24587.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL Steven Durani-24587.pdf\u003cbr\u003eOral Abstracts 627. Aggressive Lymphomas Clinical and Epidemiological Uncommon Aggressive NHL.ts\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jennifer O Sullivan-24591.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Jyoti Nangalia-24591.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Marc Usart-24591.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Matthew Stubbs-24591.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Vignir Helgason-24591.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery Yuki Tahira-24591.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Lineage Tracing and Novel Target Discovery.ts\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Billy Truong-24590.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Charlotte Brierley-24590.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Joseph Kim-24590.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Molly Brakhane-24590.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Nicole Vincelette-24590.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models Tim Kong-24590.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Oncogenic Drivers and Genetic Models.ts\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Golam Mohi-24592.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Isabelle Becker-24592.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Koki Ueda-24592.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Madeline Caduc-24592.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Naseer Basma-24592.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context Warren Fiskus-24592.pdf\u003cbr\u003eOral Abstracts 631 Myeloproliferative Syndromes and Chronic Myeloid Leukemia Basic and Translational Stromal-Immune and Signaling Context.ts\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches David Yeung-24593.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Fadi Haddad-24593.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Jorge Cortes-24593.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Qian Jiang-24593.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches Timothy Hughes-24593.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Novel Therapeutic Approaches.ts\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Andreas Hochhaus-24594.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Franck Nicolini-24594.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Frederic Millot-24594.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication Susan Branford-24594.pdf\u003cbr\u003eOral Abstracts 632. Chronic Myeloid Leukemia Clinical and Epidemiological Treatment-Free Remission and Prognostication.ts\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Harinder Gill-24595.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Naveen Pemmaraju-24595.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Sanjay Mohan-24595.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Srinivas Tantravahi-24595.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies Steffen Koschmieder-24595.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Charting The Future Of MPN Therapies.ts\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Lindsay Rein-24597.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Nico Gagelmann-24597.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Pankit Vachhani-24597.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Raajit Rampal-24597.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Rithin Nedumannil-24597.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers Yu-Hung Wang-24597.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Myelofibrosis New Therapeutic Frontiers.ts\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Andrew Kuykendall-24598.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Elliot Stieglitz-24598.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Matthieu Groh-24598.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Prithviraj Bose-24598.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Sudipto Mukherjee-24598.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies Tsewang Tashi-24598.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Rare Myeloproliferative Neoplasms Unveiling Promising Pathways and Novel Therapies.ts\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Deepika Dilip-24596.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Ellen Ritchie-24596.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Joachim Goethert-24596.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Justin Watts-24596.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs Trine Knudsen-24596.pdf\u003cbr\u003eOral Abstracts 634. Myeloproliferative Syndromes Clinical and Epidemiological Treatment and Outcomes in MPNs.ts\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Carmelo Gurnari-24599.pdf\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications He Tian (Tony) Chen-24599.pdf\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Martina Sarchi-24599.pdf\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Noah Salama-24599.pdf\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Srinivas Aluri-24599.pdf\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications Zohar Sachs-24599.pdf\u003cbr\u003eOral Abstracts 636. Myelodysplastic Syndromes – Basic and Translational Molecular Drivers and Therapeutic Implications.ts\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Elsa Bernard-24600.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Johann-Christoph Jann-24600.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Julia Montoro-24600.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Luca Lanino-24600.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Rurika Okuda-24600.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS Tariq Kewan-24600.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Genomic Classification and Prognostication of MDS.ts\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Cristina Astrid Tentori-24603.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Guillermo Garcia-Manero-24603.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Maria Diez-Campelo-24603.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Moshe Mittelman-24603.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Rami Komrokji-24603.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS Sandra Huber-24603.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatment Options and Decision Making in Low Risk MDS.ts\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Daniel Nguyen-24601.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Douglas Tremblay-24601.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jacqueline Garcia-24601.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Jan Philipp Bewersdorf-24601.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS Lok Lam Ngai-24601.pdf\u003cbr\u003eOral Abstracts 637. Myelodysplastic Syndromes – Clinical and Epidemiological Treatments and Outcome Predictions in High Risk MDS.ts\u003cbr\u003eOral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Billy Jebaraj-24604.pdf\u003cbr\u003eOral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Claudio Martines-24604.pdf\u003cbr\u003eOral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Laura Polcik-24604.pdf\u003cbr\u003eOral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Prajish Iyer-24604.pdf\u003cbr\u003eOral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation Yi Miao-24604.pdf\u003cbr\u003eOral Abstracts 641. Chronic Lymphocytic Leukemias Basic and Translational Molecular Determinants of CLL and Richter Transformation.ts\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Armin Riecke-24606.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Jennifer Brown-24606.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Moritz Furstenau-24606.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Othman Al-Sawaf-24606.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation Sarka Pavlova-24606.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Analysis and Treatment of High Risk and Treatment of Relapsed CLL or Richter Transformation.ts\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Andy Rawstron-24605.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Carol Follows-24605.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Jeff Sharman-24605.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Paolo Ghia-24605.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia Peter Hillmen-24605.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological Frontline Treatment With Targeted Agents in Patients With Chronic Lymphocytic Leukemia.ts\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Constantine Tam-24607.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Brown-24607.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Jennifer Woyach-24607.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Parag Jasani-24607.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL Tanya Siddiqi-24607.pdf\u003cbr\u003eOral Abstracts 642. Chronic Lymphocytic Leukemia Clinical and Epidemiological New Inhibitors and Cellular Therapies for Treatment of Relapsed CLL.ts\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Georgina Anderson-24613.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Laura Lucia Cogrossi-24613.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Luz Moreno Rueda-24613.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Yakinthi Chrisochoidou-24613.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia Zachary Hunter-24613.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Advancing Therapies in Multiple Myeloma and Waldenstr”m’s Macroglobulinemia.ts\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Elizabeth Lightbody-24608.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Faith Davies-24608.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Hsiling Chiu-24608.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Ross Firestone-24608.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Takahiro Kamiya-24608.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment Xiaoli Mi-24608.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterization of the MM and the Tumor Microenvironment.ts\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Deeksha Vishwamitra-24610.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Fumou Sun-24610.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Mansour Poorebrahim-24610.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Maximilian Merz-24610.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs Ram Pillarisetti-24610.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Characterizing Response and Resistance to CAR-T and TCEs.ts\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Eugenio Morelli-24609.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marcella Kaddoura-24609.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Marios Papadimitriou-24609.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Rodger Tiedemann-24609.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States Wataru Kuroki-24609.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Molecular Characterization of MM and Precursor Disease States.ts\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Anthony Cirrincione-24612.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Camila Guerrero-24612.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Elizabeth Lightbody-24612.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions Yubin Kang-24612.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions.ts\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Itziar Cenzano-24611.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Marc-Andrea Baertsch-24611.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Minghao Dang-24611.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Saurabh Zanwar-24611.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment Visanu Wanchai-24611.pdf\u003cbr\u003eOral Abstracts 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment.ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Alireza Tafazzol-24616.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Benjamin Diamond-24616.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Chunrui Li-24616.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Sahar Khan-24616.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma Yeasung Lee-24616.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Immunological Effects of Sustained Responses in Multiple Myeloma.ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Carmen Gonzalez-24620.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Elizabeth Hill-24620.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Febe Smits-24620.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Nizar Bahlis-24620.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Tadeusz Kubicki-24620.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics Yael Cohen-24620.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics.ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Carolina Schinke-24618.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Daniel Wong-24618.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Evangelos Terpos-24618.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Martin Kaiser-24618.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Theresia Akhlaghi-24618.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes Wenqiang Deng-24618.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Molecular and Biological Signatures and Predictors of Outcomes.ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Chakra Chaulagain-24617.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Cristina Perez-24617.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Efstathios Kastritis-24617.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Jon Thorir Oskarsson-24617.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Michael Wysota-24617.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc. Santiago Thibaud-24617.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Monoclonal Gammopathies of Determined Significance – Novel Insights on the Relevance of Gammopathies and Misc..ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Gaurav Agarwal-24615.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Nisha Joseph-24615.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Noemi Puig-24615.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma Yered Pita-Juarez-24615.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Novel Biomarkers for Treatment Guidance in Multiple Myeloma.ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Darren Pan-24614.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Doris Hansen-24614.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Elise Cellerin-24614.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Michel Delforge-24614.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma Sridevi Rajeeve-24614.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma.ts\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Aintzane Zabaleta-24619.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Danai Dima-24619.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Darren Pan-24619.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Junia Vieira dos Santos-24619.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Michel Delforge-24619.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications Xiang Zhou-24619.pdf\u003cbr\u003eOral Abstracts 652. Multiple Myeloma Clinical and Epidemiological T Cell Redirecting Therapy Outcomes and Associated Complications.ts\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Ajai Chari-24623.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Hang Quach-24623.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Jeffrey Matous-24623.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Paul Richardson-24623.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Sumit Madan-24623.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma Wee-Joo Chng-24623.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Relapsed and Refractory Myeloma.ts\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Cyrille Touzeau-24622.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Maria-Victoria Mateos-24622.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Niels van de Donk-24622.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Ola Landgren-24622.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma Omar Nadeem-24622.pdf\u003cbr\u003eOral Abstracts 653. Multiple Myeloma Prospective Therapeutic Trials Smoldering and Newly Diagnosed Myeloma.ts\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Efstathios Kastritis-24624.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Jahanzaib Khwaja-24624.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Moshe Gatt-24624.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Thorir Einarsson Long-24624.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis Xin Jiang-24624.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological From Light Chain to Fibril-Novel Diagnostics to Treatments for Amyloidosis.ts\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Mackenzie Maberry-24625.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Nickolas Tsakmaklis-24625.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Shayna Sarosiek-24625.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders Szymon Szymura-24625.pdf\u003cbr\u003eOral Abstracts 654. MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias Clinical and Epidemiological Screening to Vaccines-The Spectrum of Plasma Cell Disorders.ts\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Aditiya Rayasam-24626.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Albert Yeh-24626.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Chi Nguyen-24626.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Dongchang Zhao-24626.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Kristina Mott-24626.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome Marco Calafiore-24626.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational GVHD, Intestinal Immunity, and the Gut Microbiome.ts\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Andri Leo Lemarquis-24627.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution David Granadier-24627.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Fathima Mohamed-24627.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Katja Weinacht-24627.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Kevin Quann-24627.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution Lee-Kai Sun-24627.pdf\u003cbr\u003eOral Abstracts 701. Experimental Transplantation Basic and Translational T Cells in GVHD, Thymus Regeneration, and Immune Reconstitution.ts\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Jufang Chang-24629.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Lydia Lee-24629.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Meixian Huang-24629.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Varsha Sundaresan-24629.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Yusuke Ito-24629.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights Zhiliang Bai-24629.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Cellular Immunotherapy Preclinical and Translational Insights.ts\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Ivan Cohen-24628.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Jan Mueller-24628.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies Mohammad Alhomoud-24628.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Evaluating Strategies to Enhance Cellular Immunotherapies.ts\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Hongwei Ren-24631.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Jingyu Xiang-24631.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies Puneeth Guruprasad-24631.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Exploring Novel Platforms for Next-Gen CAR-Based Therapies.ts\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers James Kuzich-24633.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jay Daniels-24633.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Jort Van Der Schans-24633.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Kathryn Cappell-24633.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Mathew Angelos-24633.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers Zhenlong Li-24633.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Innovative T Cell Therapies for Unexplored Frontiers.ts\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Benjamin Goldenson-24630.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Catherine Danis-24630.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Corynn Kasap-24630.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Mylinh Bayle-24630.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies Sergio Rutella-24630.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Novel Approaches for Next Generation Cellular Immunotherapies.ts\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Janaki Manoja Vinnakota-24632.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Ruchi Patel-24632.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Shinpei Harada-24632.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Stefanie Bachl-24632.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Taisuke Kondo-24632.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights Yongxian HU-24632.pdf\u003cbr\u003eOral Abstracts 703. Cellular Immunotherapies Basic and Translational Overcoming Challenges in CAR-T Therapies Through Biological Insights.ts\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Aibin Liang-24634.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Jens Hillengass-24634.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Matthew Frigault-24634.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas Nirav Shah-24634.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas.ts\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Anand Bhagwat-24637.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Claire Roddie-24637.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Elizabeth Lihua Budde-24637.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Fabian Mueller-24637.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Peihua Lu-24637.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies Susan Bal-24637.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Expanding Disease Targets for CAR-T Cell Therapies.ts\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Jae Park-24636.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Julio Chavez-24636.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Lei Yu-24636.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Pierre Sesques-24636.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies Robert Weinkove-24636.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Improving CAR-T Therapies for B Cell Malignancies.ts\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Arjan van de Loosdrecht-24635.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Armin Ghobadi-24635.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Jessica Liegel-24635.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Nirali Shah-24635.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Samer Srour-24635.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas Yago Nieto-24635.pdf\u003cbr\u003eOral Abstracts 704. Cellular Immunotherapies Early Phase and Investigational Therapies Novel Approaches to Enhance Cellular Therapies and Immune Responses in Leukemias and Lymphomas.ts\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Adam Kittai-24638.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Alison Sehgal-24638.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Andre Goy-24638.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Jennifer Crombie-24638.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Michael Cook-24638.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data Swetha Kambhampati-24638.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for B Cell Lymphoma Prospective Clinical Trials and Real World Data.ts\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Anna Ossami Saidy-24639.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Evandro Bezerra-24639.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Gregory Roloff-24639.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Jay Spiegel-24639.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas Surbhi Sidana-24639.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Cellular Therapy for Multiple Myeloma, B-cell Acute Lymphoblastic Leukemia and B Cell Lymphomas.ts\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Kai Rejeski-24640.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Karthik Nath-24640.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Mark Hamilton-24640.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Matthew Frigault-24640.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Roni Shouval-24640.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity Zimu Gong-24640.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Prediction and Management of CAR-T Cell Related Toxicity.ts\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Ash Alizadeh-24641.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Gloria Iacoboni-24641.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Katie Maurer-24641.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Mike Mattie-24641.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors Sandeep Raj-24641.pdf\u003cbr\u003eOral Abstracts 705. Cellular Immunotherapies Late Phase and Commercially Available Therapies Translational Data and Prognostic Factors.ts\u003cbr\u003eOral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Daisuke Araki-24642.pdf\u003cbr\u003eOral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Kate Markey-24642.pdf\u003cbr\u003eOral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Laurent Garderet-24642.pdf\u003cbr\u003eOral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Natalie Holl-24642.pdf\u003cbr\u003eOral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells Yi-Jiun Su-24642.pdf\u003cbr\u003eOral Abstracts 711. Cell Collection and Processing Hematopoietic Stem Progenitor Cells Graft and Immune Effector Cells.ts\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Amado Karduss-24644.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Biqi Zhou-24644.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Filippo Milano-24644.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Reem Alasbali-24644.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool Simona Piemontese-24644.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Expanding the Donor Pool.ts\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Andrew Artz-24643.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anita Lawitschka-24643.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Anthony Sabulski-24643.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Eric Davis-24643.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Madhavi Lakkaraja-24643.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications Michael Grimley-24643.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Improving Outcomes by Reducing Transplant-Related Complications.ts\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Arpita Gandhi-24646.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hannah Choe-24646.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Hao Zheng-24646.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Ibrahim Yakoub-Agha-24646.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Marie Robin-24646.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies Xiaoyu Zhang-24646.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Novel Conditioning Regimens for Myeloid Malignancies.ts\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Bertram Glass-24645.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Caspian Oliai-24645.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Issa Khouri-24645.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Krzysztof Kalwak-24645.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia Rajni Agarwal-24645.pdf\u003cbr\u003eOral Abstracts 721. Allogeneic Transplantation Conditioning Regimens, Engraftment and Acute Toxicities Optimizing Conditioning Regimens for Lymphoid Malignancies and Fanconi Anemia.ts\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Alina Markova-24647.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Jeffery Auletta-24647.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Nikolaos Spyrou-24647.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Yu Akahoshi-24647.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management Zachariah Defilipp-24647.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Advancements in GVHD Management.ts\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Erik Thiele Orberg-24648.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Haowen Xiao-24648.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Leslie Kean-24648.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Michael Martens-24648.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology Xiaoxuan Lai-24648.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Emerging Insights in GVHD Immunobiology.ts\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Corey Cutler-24649.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Hang Zhang-24649.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Nicoletta Cieri-24649.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Ramzi Abboud-24649.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Robert Zeiser-24649.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment Zachariah Defilipp-24649.pdf\u003cbr\u003eOral Abstracts 722. Allogeneic Transplantation Acute and Chronic GVHD, Immune Reconstitution Innovative Approaches to GVHD Prevention and Treatment.ts\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Alexandria Maurer-24651.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Dustin McCurry-24651.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Hengwei Wu-24651.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Luca Vago-24651.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Nicoletta Cieri-24651.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes Shahinaz Gadalla-24651.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Basic and Translational Optimizing Post-Transplant Outcomes.ts\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Arnon Nagler-24650.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mary Eapen-24650.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Mazin Mohamed Abdulsalam-24650.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Rohtesh Mehta-24650.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Sitong Chen-24650.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations Zhihui Li-24650.pdf\u003cbr\u003eOral Abstracts 723. Allogeneic Transplantation Long-Term Follow-Up and Disease Recurrence Long-Term Survival and Survivorship From Clinical Trials And Observations.ts\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Gordon Cook-24652.pdf\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach June-Wha Rhee-24652.pdf\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Leyre Bento-24652.pdf\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Marc-Andrea Baertsch-24652.pdf\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Mazyar Shadman-24652.pdf\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach Shohei Mizuno-24652.pdf\u003cbr\u003eOral Abstracts 731. Autologous Transplantation Clinical and Epidemiological Role of Autologous Stem Cell Transplantation in Multiple Myeloma and Lymphomas A Therapeutic Approach.ts\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Arnon Nagler-24653.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Johannes Schetelig-24653.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Juan Montoro-24653.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Minoru Kanaya-24653.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection Rohtesh Mehta-24653.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Donor and Conditioning Regimen Selection.ts\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Ali Bazarbachi-24655.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Shernan Holtan-24655.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Simona Pagliuca-24655.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Timothy Voorhees-24655.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yuho Najima-24655.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation Yves Chalandon-24655.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Modern Challenges in Transplantation.ts\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Ali Bazarbachi-24654.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Benjamin Huang-24654.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Iman Abou Dalle-24654.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification Zaid Abdel Rahman-24654.pdf\u003cbr\u003eOral Abstracts 732. Allogeneic Transplantation Disease Response and Comparative Treatment Studies Use of Molecular Techniques for Risk Stratification.ts\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Alok Srivastava-24657.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside John DiPersio-24657.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Naoya Uchida-24657.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Simon Chu-24657.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Stefan Radtke-24657.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside Vincent Muczynski-24657.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies New Approaches From Bench to Bedside.ts\u003cbr\u003eOral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Franco Locatelli-24656.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Haydar Frangoul-24656.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Julie Kanter-24656.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Steven Pipe-24656.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders Ulrike Reiss-24656.pdf\u003cbr\u003eOral Abstracts 801. Gene Therapies The Long and the Short of Clinical Trials in Blood Disorders.ts\u003cbr\u003eOral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Anna Montanaro-24658.pdf\u003cbr\u003eOral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Chao-Yie Yang-24658.pdf\u003cbr\u003eOral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Lukas Kazianka-24658.pdf\u003cbr\u003eOral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Monika Toma-24658.pdf\u003cbr\u003eOral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders Samuel Taylor-24658.pdf\u003cbr\u003eOral Abstracts 802. Chemical Biology and Experimental Therapeutics Novel Targets in Blood Disorders.ts\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Arda Durmaz-24659.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Chorom Pak-24659.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Jurik Mutter-24659.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology Yoonkyu Lee-24659.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Emerging Technologies for Understanding Benign and Malignant Hematology.ts\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Andrew Srisuwananukorn-24660.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Anna Kamysheva-24660.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Catherine Lecat-24660.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Chen Zhou-24660.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Gianluca Asti-24660.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology Yoko Kawamura-24660.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Image-Based Machine Learning in Hematology.ts\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Francisco Marchi-24661.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Gianluca Asti-24661.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Jing Sun-24661.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Vikram Dhillon-24661.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology Zhongxun Shi-24661.pdf\u003cbr\u003eOral Abstracts 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology Reading the Blood Generative and Discriminative AI in Hematology.ts\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Ashish Gupta-24664.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Cecily Allen-24664.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Costa Kazadi-24664.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Lucy Fox-24664.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Shiliang Ge-24664.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology Steven Hardy-24664.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Access to Quality Care in Classical Hematology.ts\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Charles Jonassaint-24662.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Kim Smith-Whitley-24662.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Layla Van Doren-24662.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Pranav Shrestha-24662.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education Robyn Cohen-24662.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Improving Care in Sickle Cell Disease Via Technologies and Medical Education.ts\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Chiara Alessandra Cella-24663.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Ming Y Lim-24663.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Neha Bhasin-24663.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Richard Godby-24663.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Sara Mancuso-24663.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders Stacey Fedewa-24663.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Raising the bar in Anemia, Bleeding, and Thrombotic Disorders.ts\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Erica Mamauag-24665.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ifeyinwa Osunkwo-24665.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Julie Kanter-24665.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Ofelia Alvarez-24665.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Wally Smith-24665.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum Yogindra Persaud-24665.pdf\u003cbr\u003eOral Abstracts 901. Health Services and Quality Improvement – Non-Malignant Conditions Sickle Cell Disease Across the Spectrum.ts\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Aaron Cohen-24666.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Arti Vaishnav-24666.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Laura Quillen-24666.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Mia Djulbegovic-24666.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Pallavi Ganguli-24666.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias Sikander Ailawadhi-24666.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Improving Processes and Outcomes in Plasma Cell Dyscrasias.ts\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Atharva Karulkar-24668.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Matthew Gromowsky-24668.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Meng-Hsuan Lin-24668.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Patrick Connor Johnson-24668.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Radhika Bansal-24668.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy Tonya Cox-24668.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Innovative Care in CAR-T Therapy.ts\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Andrew Hantel-24667.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Chieh Yang-24667.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Jing-Zhou Hou-24667.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data Ludovic Fouillet-24667.pdf\u003cbr\u003eOral Abstracts 902. Health Services and Quality Improvement – Lymphoid Malignancies Making a Splash In Outcomes Data.ts\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christa Meyer-24669.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Christopher Su-24669.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Marissa Locastro-24669.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Pamela Egan-24669.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies Thomas Walsh-24669.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies From Blood to Bombs Identifying and Addressing Barriers to Care for Myeloid Malignancies.ts\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Ashley Hadjis-24670.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Christopher Strouse-24670.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Danielle McQuinn-24670.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Eshana Shah-24670.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Jaime Preussler-24670.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies Rahul Mishra-24670.pdf\u003cbr\u003eOral Abstracts 903. Health Services and Quality Improvement – Myeloid Malignancies Looking Below the Surface at Patient Level Predictors of Outcomes in Myeloid Malignancies.ts\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Andrew Kuykendall-24672.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jiasen He-24672.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Jordan Schaefer-24672.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Josue Marquez-24672.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Justine Ryu-24672.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients Ummul Asfeen-24672.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Across the Age Spectrum Thromboembolism Outcomes in Adult and Pediatric Patients.ts\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Charity Oyedeji-24671.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Joseph Walden-24671.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Kim Agrippa-24671.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Oliver Shastri-24671.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Rajagopalan Subramaniam-24671.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease Seethal Jacob-24671.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions Blending the Old With the New Traditional and Innovative Approaches to Determining Outcomes in Patients With Sickle Cell Disease.ts\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Antonio Risitano-24673.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders George Goshua-24673.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Nora Gibson-24673.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Satoko Ito-24673.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Shoshana Revel-Vilk-24673.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders Vincent Ho-24673.pdf\u003cbr\u003eOral Abstracts 904. Outcomes Research – Non-Malignant Conditions What to Know Management Costs and Outcomes in Various Non-Malignant Disorders.ts\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma David Cordas dos Santos-24677.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Francesco Marchesi-24677.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Ghulam Rehman Mohyuddin-24677.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Rahul Banerjee-24677.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Roberto Mina-24677.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma Shakira Grant-24677.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Balancing Efficacy, Safety and Tolerability, and Quality of Life in Patients With Multiple Myeloma.ts\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Adam Kittai-24678.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Amber Koehler-24678.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Andres Noyola-Perez-24678.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Maria Fernandez Turizo-24678.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Rockbum Kim-24678.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology Vaishali Dulobdas-24678.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology.ts\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data David Leaf-24675.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Kimberly Saverno-24675.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Mazyar Shadman-24675.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Narendranath Epperla-24675.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Nilanjan Ghosh-24675.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data Pere Barba-24675.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Lymphoma CLL Biomarkers, Dosing Strategies, and Big-Data.ts\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Alissa Visram-24674.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Doris Hansen-24674.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Fieke Hoff-24674.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Hira Mian-24674.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Inger Nijhof-24674.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New Meera Mohan-24674.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Outcomes Research in Myeloma What’s New.ts\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Amy Wang-24676.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Annalynn Williams-24676.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Benoit Tessoulin-24676.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Guillaume Cartron-24676.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies Timothy OConnor-24676.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Patient Reported Outcomes in Hematological Malignancies.ts\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Gin Yi Lee-24679.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Jorge Florindez-24679.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Kaitlin Annunzio-24679.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Mustafa Wasifuddin-24679.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Narendranath Epperla-24679.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma Niloufer Khan-24679.pdf\u003cbr\u003eOral Abstracts 905. Outcomes Research – Lymphoid Malignancies Practice Changing Patient-Reported Outcome Measurements and Real World Evidence Studies in Patients With Lymphoma.ts\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Alice Mims-24682.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Amer Zeidan-24682.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Caitlin Elgarten-24682.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Diego Adrianzen Herrera-24682.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Emanuele Angelucci-24682.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes Nosakhare Ilerhunmwuwa-24682.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Real-World Treatment Patterns and Outcomes.ts\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Alma Habib-24681.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Daniel Zheng-24681.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Jeffrey Rubnitz-24681.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michael Grunwald-24681.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Michelle Lee-24681.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities Teresa Caprice-24681.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Risk Factors and Health Disparities.ts\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Areej El-Jawahri-24680.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Diego Adrianzen Herrera-24680.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Esther Oliva-24680.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Kirollos Hanna-24680.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies Valeria Santini-24680.pdf\u003cbr\u003eOral Abstracts 906. Outcomes Research – Myeloid Malignancies Symptom Burden and Supportive Therapies.ts\u003cbr\u003eScientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Linde Miles-24146.pdf\u003cbr\u003eScientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Mark Dawson-24146.pdf\u003cbr\u003eScientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies Seishi Ogawa-24146.pdf\u003cbr\u003eScientific Program Co-Operativity in the Pathogenesis of Myeloid Malignancies.ts\u003cbr\u003eScientific Program Emerging Methodologies to Investigate Platelet Biology Andrew Johnson-24144.pdf\u003cbr\u003eScientific Program Emerging Methodologies to Investigate Platelet Biology Anita Eckly-24144.pdf\u003cbr\u003eScientific Program Emerging Methodologies to Investigate Platelet Biology Florian Gaertner-24144.pdf\u003cbr\u003eScientific Program Emerging Methodologies to Investigate Platelet Biology.ts\u003cbr\u003eScientific Program Interplay of Coagulation and Complement in Transfusion Medicine Demin Wang-24150.pdf\u003cbr\u003eScientific Program Interplay of Coagulation and Complement in Transfusion Medicine Rick Kapur-24150.pdf\u003cbr\u003eScientific Program Interplay of Coagulation and Complement in Transfusion Medicine Satheesh Chonat-24150.pdf\u003cbr\u003eScientific Program Interplay of Coagulation and Complement in Transfusion Medicine.ts\u003cbr\u003eScientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Dachuan Zhang-24143.pdf\u003cbr\u003eScientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis Leon Kautz-24143.pdf\u003cbr\u003eScientific Program Iron and Heme in Stem Cell Maintenance and Erythropoiesis.ts\u003cbr\u003eScientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Alexander Marson-24142.pdf\u003cbr\u003eScientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Carl June-24142.pdf\u003cbr\u003eScientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Chiara Bonini-24142.pdf\u003cbr\u003eScientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy Dan Kaufman-24142.pdf\u003cbr\u003eScientific Program Joint Session Genome Engineering for Enhanced Blood Cancer Immunotherapy.ts\u003cbr\u003eScientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Aswin Sekar-24139.pdf\u003cbr\u003eScientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Laura Pasqualucci-24139.pdf\u003cbr\u003eScientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies Mandeep Singh-24139.pdf\u003cbr\u003eScientific Program Joint Session Lymphomagenesis – What Normal Immunology, Abnormal Immunology, and Genomics Can Teach Us About Lymphoma Biology and Novel Therapeutic Strategies.ts\u003cbr\u003eScientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Alan Cantor-24145.pdf\u003cbr\u003eScientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Anna Beaudin-24145.pdf\u003cbr\u003eScientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood Shannon McKinney-Freeman-24145.pdf\u003cbr\u003eScientific Program Joint Session Ontogeny and Myeloid Disorders of Childhood.ts\u003cbr\u003eScientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Alyssa Kennedy-24137.pdf\u003cbr\u003eScientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Jean Soulier-24137.pdf\u003cbr\u003eScientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes Sushree Sahoo-24137.pdf\u003cbr\u003eScientific Program Mechanisms of Genetic Rescue in Inherited Bone Marrow Failure Syndromes.ts\u003cbr\u003eScientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Evi Stavrou-24149.pdf\u003cbr\u003eScientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Ioannis Mitroulis-24149.pdf\u003cbr\u003eScientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis Kimberly Martinod-24149.pdf\u003cbr\u003eScientific Program Mechanistic Role(s) of Neutrophil Extracellular Traps in Thrombosis.ts\u003cbr\u003eScientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Jeroen Eikenboom-24141.pdf\u003cbr\u003eScientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Leah Sabin-24141.pdf\u003cbr\u003eScientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders Lindsey George-24141.pdf\u003cbr\u003eScientific Program Next Generation of Gene-Based Therapies for Bleeding Disorders.ts\u003cbr\u003eScientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Jordan Shavit-24136.pdf\u003cbr\u003eScientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Pavel Davizon-Castillo-24136.pdf\u003cbr\u003eScientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome Suzan Williams-24136.pdf\u003cbr\u003eScientific Program Pre- and Post-Thrombus Risk Factors of Clotting and Post-Thrombosis Syndrome.ts\u003cbr\u003eScientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Daniel Lucas-Alcaraz-24140.pdf\u003cbr\u003eScientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Maria Carolina Florian-24140.pdf\u003cbr\u003eScientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis Tiago Luis-24140.pdf\u003cbr\u003eScientific Program Single Cell Omics and High Resolution Imaging to Unravel the Role of the Niche in Stress and Ageing Hematopoiesis.ts\u003cbr\u003eScientific Program Spatial Genomic \u0026amp; Epigenomic Profiling in Hematology Elham Azizi-24138.pdf\u003cbr\u003eScientific Program Spatial Genomic \u0026amp; Epigenomic Profiling in Hematology Fei Chen-24138.pdf\u003cbr\u003eScientific Program Spatial Genomic \u0026amp; Epigenomic Profiling in Hematology Rong Fan-24138.pdf\u003cbr\u003eScientific Program Spatial Genomic \u0026amp; Epigenomic Profiling in Hematology.ts\u003cbr\u003eScientific Program The Evolution of Multiple Myeloma From Inside-Out Eugenio Morelli-24147.pdf\u003cbr\u003eScientific Program The Evolution of Multiple Myeloma From Inside-Out Marta Chesi-24147.pdf\u003cbr\u003eScientific Program The Evolution of Multiple Myeloma From Inside-Out Tom Cupedo-24147.pdf\u003cbr\u003eScientific Program The Evolution of Multiple Myeloma From Inside-Out.ts\u003cbr\u003eScientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Ann Dean-24148.pdf\u003cbr\u003eScientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Gerd Blobel-24148.pdf\u003cbr\u003eScientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression Mitchell Weiss-24148.pdf\u003cbr\u003eScientific Program The Long Non-Coding Road, RNA and Signaling, and Regulation of Globin Gene Expression.ts\u003cbr\u003eScientific Symposia Alternative Immune Effector Cells Evan Weber-24835.pdf\u003cbr\u003eScientific Symposia Alternative Immune Effector Cells James Cronk-24835.pdf\u003cbr\u003eScientific Symposia Alternative Immune Effector Cells Marie Bleakley-24835.pdf\u003cbr\u003eScientific Symposia Alternative Immune Effector Cells.ts\u003cbr\u003eScientific Symposia Multi-Omics Driven Precision Hematology Jun J. Yang-24836.pdf\u003cbr\u003eScientific Symposia Multi-Omics Driven Precision Hematology Mika Kontro-24836.pdf\u003cbr\u003eScientific Symposia Multi-Omics Driven Precision Hematology Pamela Becker-24836.pdf\u003cbr\u003eScientific Symposia Multi-Omics Driven Precision Hematology.ts\u003cbr\u003eScientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Caterina Casari-24833.pdf\u003cbr\u003eScientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis Matthew Flick-24833.pdf\u003cbr\u003eScientific Symposia Special Symposium on the Basic Science in Hemostasis and Thrombosis.ts\u003cbr\u003eScientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Ami Smith-24834.pdf\u003cbr\u003eScientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Kate Markey-24834.pdf\u003cbr\u003eScientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies Marcel van den Brink-24834.pdf\u003cbr\u003eScientific Symposia The Impact of the Microbiota on Immunotherapy of Hematological Malignancies.ts\u003cbr\u003eScientific Symposia Understanding Sickle Cell Pathophysiology Enrico Novelli-24837.pdf\u003cbr\u003eScientific Symposia Understanding Sickle Cell Pathophysiology Jeffrey Chalmers-24837.pdf\u003cbr\u003eScientific Symposia Understanding Sickle Cell Pathophysiology Lucia De Franceschi-24837.pdf\u003cbr\u003eScientific Symposia Understanding Sickle Cell Pathophysiology.ts\u003cbr\u003eSpecial-Interest Sessions 2023 ASH Guideline Implementation Champions Christina Ruiz-24365.pdf\u003cbr\u003eSpecial-Interest Sessions 2023 ASH Guideline Implementation Champions Gabriella Nguyen-24365.pdf\u003cbr\u003eSpecial-Interest Sessions 2023 ASH Guideline Implementation Champions.ts\u003cbr\u003eSpecial-Interest Sessions AI in Hematology Where Do You Stand in 2023 Torsten Haferlach-24388.pdf\u003cbr\u003eSpecial-Interest Sessions AI in Hematology Where Do You Stand in 2023 Weida Tong-24388.pdf\u003cbr\u003eSpecial-Interest Sessions AI in Hematology Where Do You Stand in 2023 Yates Coley-24388.pdf\u003cbr\u003eSpecial-Interest Sessions AI in Hematology Where Do You Stand in 2023.ts\u003cbr\u003eSpecial-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Alessandra Ferrajoli-24366.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Ayman Alhejazi-24366.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions Vilmarie Rodriguez-24366.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Choosing Wisely Campaign 2023 ASH Choosing Wisely Champions.ts\u003cbr\u003eSpecial-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Aaron Goodman-24159.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Benjamin Tillman-24159.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients David Andorsky-24159.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients Shannon Walker-24159.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Clinicians in Practice (ACIP) Lunch – How Can We Provide Sustainable Care to Hematology Patients.ts\u003cbr\u003eSpecial-Interest Sessions ASH Grassroots Network Lunch.ts\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Julie Wolfson-24153.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Sumit Gupta-24153.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults Wendy Stock-24153.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults.ts\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Deborah Siegal-24152.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Saskia Middeldorp-24152.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New Suely Rezende-24152.pdf\u003cbr\u003eSpecial-Interest Sessions ASH Guidelines on Venous Thromboembolism (VTE) What’s New.ts\u003cbr\u003eSpecial-Interest Sessions Blood and Beyond.ts\u003cbr\u003eSpecial-Interest Sessions Junior Faculty Career Development Session Cassandra Josephson-24155.pdf\u003cbr\u003eSpecial-Interest Sessions Junior Faculty Career Development Session Oyebimpe Adesina-24155.pdf\u003cbr\u003eSpecial-Interest Sessions Junior Faculty Career Development Session Srinivas Devarakonda-24155.pdf\u003cbr\u003eSpecial-Interest Sessions Junior Faculty Career Development Session.ts\u003cbr\u003eSpecial-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Alison Loren-24158.pdf\u003cbr\u003eSpecial-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Erica Marsh-24158.pdf\u003cbr\u003eSpecial-Interest Sessions Maternal Health Fertility Preservation in Hematology Care Mindy Christianson-24158.pdf\u003cbr\u003eSpecial-Interest Sessions Maternal Health Fertility Preservation in Hematology Care.ts\u003cbr\u003eSpecial-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Alisa Wolberg-24154.pdf\u003cbr\u003eSpecial-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Nicole Gormley-24154.pdf\u003cbr\u003eSpecial-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community Saad Usmani-24154.pdf\u003cbr\u003eSpecial-Interest Sessions Special Scientific Session on Race and Science Bench to Bedside to the Community.ts\u003cbr\u003eSpecial-Interest Sessions Special Session on Sickle Cell Disease Centers Alexis Leonard-24422.pdf\u003cbr\u003eSpecial-Interest Sessions Special Session on Sickle Cell Disease Centers Julie Kanter-24422.pdf\u003cbr\u003eSpecial-Interest Sessions Special Session on Sickle Cell Disease Centers Sophie Lanzkron-24422.pdf\u003cbr\u003eSpecial-Interest Sessions Special Session on Sickle Cell Disease Centers.ts\u003cbr\u003eSpecial-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Alexandra Power-Hays-24151.pdf\u003cbr\u003eSpecial-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Allison Burnett-24151.pdf\u003cbr\u003eSpecial-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care Geoffrey Barnes-24151.pdf\u003cbr\u003eSpecial-Interest Sessions Special Symposium on Quality – Identifying and Addressing Underuse in Hematologic Care.ts\u003cbr\u003eSpecial-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Sandhya Panch-24367.pdf\u003cbr\u003eSpecial-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation Surbhi Shah-24367.pdf\u003cbr\u003eSpecial-Interest Sessions Systems-Based Hematology Education and Networking Session Hematology E-Consultation.ts\u003cbr\u003eSpotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ludmila Prokunina-Olsson-24831.pdf\u003cbr\u003eSpotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma Ryan Morin-24831.pdf\u003cbr\u003eSpotlight Sessions Advances in Genomics Tools Finally Opening the Molecular Secrets of Burkitt Lymphoma.ts\u003cbr\u003eSpotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Deborah Siegal-24130.pdf\u003cbr\u003eSpotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors Sam Schulman-24130.pdf\u003cbr\u003eSpotlight Sessions Debate PCC or Andexanet alfa for Managing Bleeding in Patients on Oral Xa Inhibitors.ts\u003cbr\u003eSpotlight Sessions Immunometabolism as a Tool to Advance Cell Therapy.ts\u003cbr\u003eSpotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Paolo Ghia-24131.pdf\u003cbr\u003eSpotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL Zhuoer Xie-24131.pdf\u003cbr\u003eSpotlight Sessions Managing Previvorship in Hematology Clinical Approaches to CCUS and MBL.ts\u003cbr\u003eSpotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Srinivas Devarakonda-24830.pdf\u003cbr\u003eSpotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients Yvonne Efebera-24830.pdf\u003cbr\u003eSpotlight Sessions Tackling Greater Burden of Multiple Myeloma in African American Patients.ts\u003cbr\u003eSpotlight Sessions The Mysteries of Factor XI David Gailani-24832.pdf\u003cbr\u003eSpotlight Sessions The Mysteries of Factor XI Ophira Salomon-24832.pdf\u003cbr\u003eSpotlight Sessions The Mysteries of Factor XI.ts\u003cbr\u003eSpotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution John Mark Sloan-24128.pdf\u003cbr\u003eSpotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution Lauren Merz-24128.pdf\u003cbr\u003eSpotlight Sessions What is a “Normal” Neutrophil Count The Duffy Red Cell Antigen, Ancestry, Genetics and Evolution.ts\u003cbr\u003eSpotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Justin Taylor-24132.pdf\u003cbr\u003eSpotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials Valeria Santini-24132.pdf\u003cbr\u003eSpotlight Sessions Where the Bench Meets the Bedside Laboratory Correlates in Clinical Trials.ts\u003cbr\u003eSpotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Carlos Ramos-24129.pdf\u003cbr\u003eSpotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes Jonathan Fisher-24129.pdf\u003cbr\u003eSpotlight Sessions Who are the Alternatives for Cellular Therapies Engineering and Retargeting Other Effector Lymphocytes.ts\u003cbr\u003eTrainee Didactic Session A Road Less Traveled – Careers Outside of Academia Amber Yates-24862.pdf\u003cbr\u003eTrainee Didactic Session A Road Less Traveled – Careers Outside of Academia Timothy Kubal-24862.pdf\u003cbr\u003eTrainee Didactic Session A Road Less Traveled – Careers Outside of Academia.ts\u003cbr\u003eTrainee Didactic Session Show Me the Money – Funding Your Research Cassandra Josephson-24865.pdf\u003cbr\u003eTrainee Didactic Session Show Me the Money – Funding Your Research Ifeyinwa Osunkwo-24865.pdf\u003cbr\u003eTrainee Didactic Session Show Me the Money – Funding Your Research.ts\u003cbr\u003eTrainee Didactic Session The International Trainee Journey Andres Gomez-De Leon-24160.pdf\u003cbr\u003eTrainee Didactic Session The International Trainee Journey Eloisa Riva-24160.pdf\u003cbr\u003eTrainee Didactic Session The International Trainee Journey.ts\u003cbr\u003eTrainee Didactic Session What to Ask For in an Interview Alison Walker-24867.pdf\u003cbr\u003eTrainee Didactic Session What to Ask For in an Interview.ts\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954367303778,"sku":"MED-AMB02026","price":100.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/65th-ASH-Annual-Meeting-Exposition.png?v=1779374740","url":"https:\/\/meducourse.com\/products\/65th-ash-annual-meeting-exposition","provider":"Meducourse","version":"1.0","type":"link"}